Evotec has initiated a “priority reset” to focus on profitable growth areas gaining momentum and building on core strengths.   The reset aims to achieve expected annualized adjusted EBITDA improvement of over €40 million starting in 2H24, through the exit of gene therapy and closing the site in Orth, Austria, and closure of Chemistry activities in Marcy (Lyon, France), the separation of manufacturing in Halle/Westphalia, Germany as non-core activity. Additionally, the company will reduce headc...